Headlines of The Day
Metropolis records 26% YoY growth for non-covid business
Metropolis Healthcare Ltd. announced its unaudited consolidated financial results today for the first quarter of financial year 2023.
Q1FY23 key highlights
- Non-Covid Home Visits revenue increased by 30% YoY Rs. 23 Crs.
- Specialized tests contributed 42% to the Non-Covid revenue
- EBITDA margin (Before CSR & ESOP) stood at 25.6%
Q1FY23 financial highlights
“I am extremely pleased to share that we have recorded 26% growth on year-on-year basis for non-covid business inspite of the challenging business environment. Covid and Covid allied revenue witnessed a sharp fall as expected in line with the drop in number of covid cases. Going ahead, we expect the non-covid revenue to revert back to the sustainable growth rates recorded in pre-covid days.
We at Metropolis will continue to build our scientific capabilities, expand our network of labs and patient collection centres, build a superior customer experience, and will also focus on wellness and chronic testing segment. We are excited about the differentiation we have been able to create over the years and believe our company has a long runway of growth.” Ameera Shah, Promoter and Managing Director, Metropolis Healthcare Ltd.
| In INR Crs. | Q1FY23 | Q1FY22 |
| Revenue from operations | 279.9 | 326.8 |
| EBIDTA (before CSR & ESOP) | 71.7 | 105.6 |
| EBIDTA margin (before CSR & ESOP) | 25.6% | 32.3% |
| Profit after tax | 33.6 | 63.0* |
| PAT margin (%) | 12.0% | 19.3% |
MB Bureau
